ERIS - IntraDay Trade Analysis with Live Signals

Last Updated Time : 05 Nov 25, 7:43 am

IntraDay Trade Rating: 3.2

📉 Weak momentum and low volume make ERIS a cautious intraday candidate. Better suited for swing trades.

🔍 Positive

• Quarterly PAT surged from ₹30.5 Cr. to ₹100 Cr., showing strong earnings rebound.
• DII holding increased by 1.18%, signaling domestic institutional confidence.
• Trading near 200 DMA (₹1,554) offers technical support.

⚠️ Limitation

• MACD negative (-9.26) and RSI below 50 (45.4) indicate weak momentum.
• Volume significantly below 1-week average, suggesting low intraday interest.
• High P/E (135) vs industry average (33.1) implies valuation risk.
• Debt-to-equity ratio of 0.89 is relatively high for pharma sector.

📰 Company Negative News

• FII holding dropped by 1.18%, indicating reduced foreign investor confidence.

📢 Company Positive News

• Quarterly profit growth of 487% highlights strong operational turnaround.

🏭 Industry

• Pharma sector remains defensive but faces pricing pressure and regulatory challenges.
• Industry P/E of 33.1 suggests moderate valuation across peers.

🧾 Conclusion

• ERIS shows weak intraday momentum and low volume, making it a cautious candidate for day trading.
• Ideal for swing or positional trades unless volume and RSI improve intraday.
• Use tight stop loss and monitor price action near DMA levels for exit cues.

I can track ERIS’s live MACD and RSI shifts to notify you when momentum improves for a better entry.